Scientific commentary highlights the impact of fibroblast growth factor 23 on erythropoiesis across iron deficiency and kidney disease, suggesting new therapeutic targets for anemia.
In this issue of Blood, Courbon et al 1 describe the effects of the phosphateregulating hormone fibroblast growth factor 23 (FGF23) on erythropoiesis in health, iron deficiency, and chronic kidney disease (CKD).
No takes yet. Share an insight, caveat, or question.
Myles Wolf (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: